84 related articles for article (PubMed ID: 1722797)
1. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
el Etreby MF; Nishino Y; Habenicht UF; Henderson D
J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
[TBL] [Abstract][Full Text] [Related]
2. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
el Etreby MF
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838
[TBL] [Abstract][Full Text] [Related]
3. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
[TBL] [Abstract][Full Text] [Related]
4. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
Habenicht UF; el Etreby MF
J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
[TBL] [Abstract][Full Text] [Related]
5. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837
[TBL] [Abstract][Full Text] [Related]
6. Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings.
Suzuki K; Ito K; Tamura Y; Suzuki T; Honma S; Yamanaka H
Prostate; 1996 May; 28(5):328-37. PubMed ID: 8610061
[TBL] [Abstract][Full Text] [Related]
7. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H
Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202
[TBL] [Abstract][Full Text] [Related]
8. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
9. Effects of estrogen deprivation on human benign prostatic hyperplasia.
Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839
[TBL] [Abstract][Full Text] [Related]
10. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group.
Gingell JC; Knönagel H; Kurth KH; Tunn UW
J Urol; 1995 Aug; 154(2 Pt 1):399-401. PubMed ID: 7541854
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Nishino Y; Schneider MR; Michna H; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy for benign prostatic hyperplasia in the 90's.
Ekman P
J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
[TBL] [Abstract][Full Text] [Related]
13. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.
Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF
Prostate; 1986; 8(2):181-94. PubMed ID: 2419882
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.
Oesterling JE; el Etreby MF; Gormley GJ; Imperato-McGinley JL; Roehrborn CG; Schröder FH; Tunn UW
Prog Clin Biol Res; 1994; 386():231-50. PubMed ID: 7528391
[TBL] [Abstract][Full Text] [Related]
15. Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
Brodie AM; Son C; King DA; Meyer KM; Inkster SE
Cancer Res; 1989 Dec; 49(23):6551-5. PubMed ID: 2479464
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD).
Habenicht UF; el Etreby MF
Prostate; 1989; 14(4):309-22. PubMed ID: 2473459
[TBL] [Abstract][Full Text] [Related]
17. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin.
Boehm S; Nirnberger G; Ferrari P
Wien Klin Wochenschr; 1998 Dec; 110(23):817-23. PubMed ID: 10025034
[TBL] [Abstract][Full Text] [Related]
18. The function and the role of aromatase inhibitors in the treatment of BPH.
el Etreby MF; Habenicht UF
Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389
[No Abstract] [Full Text] [Related]
19. Anti-androgen effects of the aromatase inhibitor, atamestane.
Shao TC; Marcelli M; Kong A; Cunningham GR
J Androl; 1995; 16(2):100-7. PubMed ID: 7559139
[TBL] [Abstract][Full Text] [Related]
20. [Aromatase inhibitors in the medical treatment of benign prostatic hypertrophy].
Tunn UW; Goldschmidt AJ
J Urol (Paris); 1993; 99(6):307. PubMed ID: 7516374
[No Abstract] [Full Text] [Related]
[Next] [New Search]
